title: Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding.
abstract: Anticonvulsant levels decline as pregnancy progresses, even in the face of constant and, in some cases, increased dosages of medications. It has been suggested that this decline is responsible for the increase in seizure frequency seen in approximately one-third of the women with epilepsy who become pregnant. Changes in plasma protein binding may explain the declines in anticonvulsant concentrations during pregnancy. A prospective cohort study was designed to test this hypothesis. Carbamazepine, phenytoin and phenobarbital were studied. The mean total concentrations of all 3 drugs declined as pregnancy progressed, rising in the postpartum period. Free concentrations also declined, but did so significantly only for phenobarbital. The free fraction for all anticonvulsants studied rose significantly throughout pregnancy. Protein binding is significantly altered during pregnancy for all 3 drugs studied and appears to account for much of the decline in anticonvulsant concentrations seen in this condition. It is suggested that free rather than total drug concentrations be monitored in pregnant women with epilepsy.
authors.affiliation: Epilepsy Research Center, Department of Neurology, University of Minnesota, Minneapolis 55414.
authors.forename: M S
authors.initials: MS
authors.lastname: Yerby
authors.forename: P N
authors.initials: PN
authors.lastname: Friel
authors.forename: K
authors.initials: K
authors.lastname: McCormick
authors.forename: M
authors.initials: M
authors.lastname: Koerner
authors.forename: M
authors.initials: M
authors.lastname: Van Allen
authors.forename: A M
authors.initials: AM
authors.lastname: Leavitt
authors.forename: C J
authors.initials: CJ
authors.lastname: Sells
authors.forename: J A
authors.initials: JA
authors.lastname: Yerby
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001798:Blood Proteins / Q000378:metabolism*; D002220:Carbamazepine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D010634:Phenobarbital / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010672:Phenytoin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000378:metabolism*
chemical_list: D000927:Anticonvulsants; D001798:Blood Proteins; D002220:Carbamazepine; D010672:Phenytoin; D010634:Phenobarbital